Xiamen Wantai

Understanding Wantai Canghai: Xiamen Wantai Canghai Biotechnology Co., Ltd. is affiliated with Wantai Biologics under the Yangshengtang Group. Yangshengtang Co., Ltd. [Nongfu Spring Stock Code: 09633] is among China's top 500 private enterprises, with industries spanning five major fields: health products, food, beverages, cosmetics, and biopharmaceuticals. It has created several well-known brands, such as Nongfu Spring, Mother's Beef Jerky, Yangshengtang Natural VC/VE, and Birch Tree Juice Mask. In 2001, Yangshengtang Group acquired Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. [Wantai Biologics Stock Code: 603392]. Wantai Biologics is a core enterprise in the biopharmaceutical field, focusing on two major business segments: diagnostic reagents and innovative vaccines. Wantai Biologics is a major production base for HIV diagnostic reagents in the Asia-Pacific region and a main manufacturer of immune in vitro diagnostic reagents in China. It has nine subsidiaries, each specializing in the research, development, production, and sales of innovative vaccines, new diagnostic reagents, high-end medical instruments, and bioactive raw materials. Xiamen Wantai Canghai Biotechnology Co., Ltd. is a backbone enterprise in the vaccine segment of Wantai Biologics, focusing on the transformation of industry-academia-research achievements in innovative vaccines. [Xiamen Wantai Canghai Biotechnology Co., Ltd.] Xiamen Wantai Canghai Biotechnology Co., Ltd. was established in March 2005 with a registered capital of 1.2 billion yuan. It is a backbone enterprise in the vaccine segment of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., under the well-known domestic enterprise "Yangshengtang," and is the only private science and technology enterprise in Fujian Province engaged in vaccine research, development, and production to date. Since its inception, the company has been deeply committed to the vaccine industry for over 20 years, dedicated to providing high-quality and affordable innovative vaccines for human disease prevention. Relying on the "National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD)" jointly established by Yangshengtang and Xiamen University, the company explores a sustainable industry-academia-research model. It has established an E. coli virus-like particle technology platform with independent intellectual property rights, and has successfully developed and launched the world's first recombinant hepatitis E vaccine (Hecolin®), China's first domestic bivalent HPV vaccine (Cecolin®), and China's first and the world's second nine-valent HPV vaccine (Cecolin®9), among other significant innovative vaccine products. Additionally, there are pipeline products such as recombinant respiratory syncytial virus vaccine and third-generation HPV vaccine. The company has achieved significant accomplishments in multiple fields, being a "National High-tech Enterprise," "National and Local Joint Engineering Laboratory," and approved to establish a national postdoctoral research workstation. Its star product, the hepatitis E vaccine, has received awards including the "Innovation Achievement Award for the 60th Anniversary of the People's Republic of China," "Best Technology Innovation Award in Asia," and "China Patent Gold Award," while the bivalent HPV vaccine has obtained WHO PQ certification.